NCT06590623

Brief Summary

To conduct a single-arm pilot study to determine how acute ingestion of an exogenous ketone monoester supplement alters the histone lysine β-hydroxybutyrylation and immune function in healthy human monocytes and lymphocytes.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 5, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
12 days until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

March 7, 2025

Status Verified

March 1, 2025

Enrollment Period

8 months

First QC Date

September 5, 2024

Last Update Submit

March 4, 2025

Conditions

Keywords

Ketone supplementExogenous ketonesImmune functionβ-hydroxybutyrylationBeta-Hydroxybutyrate

Outcome Measures

Primary Outcomes (1)

  • β-hydroxybutyrylation of histone in human immune cells using Western blotting

    The β-hydroxybutyrylation of histones in human monocytes and lymphocytes will be assessed before and 2 hours after the consumption of an exogenous ketone supplement. Protein samples will be collected from the cells, and the levels of histone β-hydroxybutyrylation will be quantified using Western blotting.

    Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.

Secondary Outcomes (7)

  • Change in beta-hydroxybutyrate concentration

    Capillary beta-hydroxybutyrate will be measured before, 30, 60, 90, 120 and 180 minutes after the consumption of exogenous ketone supplement.

  • Change in glucose concentration

    Capillary glucose concentration will be measured before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.

  • Change in blood pressure

    Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.

  • Change in resting heart rate

    Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.

  • Alteration in immune cell functions

    Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.

  • +2 more secondary outcomes

Study Arms (1)

exogenous ketone supplement

EXPERIMENTAL

Participants will consume a ketone monoester supplement (KetoneAid KE4) at a dose of 0.75 g/kg of body weight.

Dietary Supplement: Ketone Monoester (KE)

Interventions

Ketone Monoester (KE)DIETARY_SUPPLEMENT

Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.

Also known as: Exogenous ketone
exogenous ketone supplement

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over the age of 19
  • Able to fast overnight

You may not qualify if:

  • Being a competitive endurance athlete.
  • Following a ketogenic diet, low-calorie diet, periodic fasting regimen, or regularly consuming ketogenic supplements.
  • Being unable to travel to and from the university
  • Being pregnant.
  • Having been diagnosed with a chronic disorder of glucose or fat metabolism, including type 2 diabetes, chronic pancreatitis, or gallbladder disease
  • Being unable to read or communicate in English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of British Columbia Okanagan Campus

Kelowna, British Columbia, V1V1V7, Canada

RECRUITING

MeSH Terms

Conditions

KetosisMotor Activity

Condition Hierarchy (Ancestors)

AcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesBehavior

Central Study Contacts

Jonathan Little Principal Investigator, Professor Little, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 5, 2024

First Posted

September 19, 2024

Study Start

October 1, 2024

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

March 7, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

IPD will not be shared to ensure the privacy and confidentiality of participants, in accordance with ethical guidelines and data protection regulations. Additionally, this was not included in the informed consent, which did not cover data sharing or address potential risks of re-identification.

Locations